907-P: Striking Improvements in HbA1c following Commencement of Flash Glucose Monitoring in Type 1 Diabetes
| Autor: | Anna R. Dover, Nicola N. Zammitt, Stuart A. Ritchie, Victoria Tyndall, Fraser W. Gibb, John A. McKnight, Roland H Stimson |
|---|---|
| Rok vydání: | 2019 |
| Předmět: |
Pediatrics
medicine.medical_specialty Type 1 diabetes business.industry Endocrinology Diabetes and Metabolism Hypoglycemia medicine.disease Hospital Anxiety and Depression Scale National health service Prescription data Diabetes mellitus Internal Medicine medicine business Prospective cohort study Glycemic |
| Zdroj: | Diabetes. 68 |
| ISSN: | 1939-327X 0012-1797 |
| DOI: | 10.2337/db19-907-p |
| Popis: | Little evidence currently supports the efficacy of Flash Monitoring (FM) in type 1 diabetes. We present the largest prospective study of clinical outcomes following FM. National Health Service (NHS) funding for FM was introduced in Feb 2018 in our center. We evaluated outcomes in 900 people with T1DM. Baseline HbA1c was the most recent value prior to commencing FM. Control HbA1c data were obtained from 518 people with no prior or current FM use. Pre- and post-FM hypoglycemia and Hospital Anxiety and Depression Scale (HADS) data were available in 57%. Hospital admission and test-strip prescription data were obtained for the 6 months following NHS-funding and the corresponding period the previous year. Median age was 42 years (IQR 30 - 55). Mean baseline HbA1c was 65±15 mmol/mol. Pre-FM, 34.2% had HbA1c 75 mmol/mol (9.0%) fell from 17.8% to 8.5%, P < 0.001. Mean reduction in HbA1c was 5.6±10.9 mmol/mol (P < 0.001) but was greater in those with baseline HbA1c above 75mmol/mol (-15.4±16.8 mmol/mol, P < 0.001). In the control group, HbA1c did not change across the corresponding period (+0.2 mmol/mol, P = 0.66). In multivariate analysis, less frequent SMBG pre-FM (P = 0.03), higher HbA1c (P FM is associated with reduced DKA admissions and marked improvement in glycemic control across a wide range of people with T1DM. Disclosure F.W. Gibb: None. R.H. Stimson: None. J.A. McKnight: Other Relationship; Self; Boehringer Ingelheim International GmbH, Lilly Diabetes, MedImmune, Novo Nordisk Inc. V. Tyndall: None. S.A. Ritchie: Other Relationship; Self; MedImmune, Novo Nordisk Inc. N.N. Zammitt: None. A.R. Dover: Other Relationship; Self; Abbott. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|